for CTMX follow this critical thread on Twitter on their anti PD1
$CTMX Stock is down 35% since ASCO. Why? After all, their whole value prop is that they can improve the safety profile of the PD(L)-1+CTLA-4 combo. Indeed,sellsiders like Jefferies's Amin parrot the company party line, that GR 3/4 TRAE of 31% were lower than Yervoy alone! pic.twitter.com/AXrRotkBWi
for NKTR they present at the ASCO-SITC Clinical Immuno-Oncology Symposium - abstract (with data from 06 Nov) here https://meetinglibrary.asco.org/record/170573/abstract - [given the 9 week cycle for efficacy evaluation, i.e. probably one observation extra for each patient:] you will have to make yourself an educated opinion on the continued effects on the 7 patients that already had their first efficiency evaluation reported and perhaps ~ 4-5 additional patients that were not evaluated - SITC 2018 data can be found on slide 29 onwards here https://ir.nektar.com/static-files/55ab4915-ea79-42e6-9f40-d49fa3a9b1c3 - what I noted that the only PR (as of SITC) were in melanoma
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.